Gain detailed insights into the trading activity of Congress members for CSL on our government trades page. Stay updated on how elected officials are investing in CSLLY.

CSL - Government Trades

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

GileadSciences.Shutterstock

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ABBV

CSLLY

GILD

Wall Street&#39;s Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

10 Reasons Michigan's Bird Flu Strategy Is Stirring COVID-Era Anxiety In Farming Communities

Biotech

Government

Large Cap

Health Care

Financing

General

The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5 cases.

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report

10 Alarming Facts About FLiRT And LB.1, The New COVID Variants Reshaping The Pandemic

Equities

ARCT

CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer&#39;s Comirnaty in a Phase 3 study, persisting for one year and at a lower dose.

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer&#39;s Comirnaty Shot, Even At Lower Doses

Pfizer_shutterstock2

FDA Green Lights Pfizer&#39;s Gene Therapy For Rare Bleeding Disorder Hemophilia

Analyst Color

Initiation

Small Cap

Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.

Arcturus Therapeutics&#39; Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside

Penny Stocks

Tech

Media

BBBY

EADSF

European Aeronautic Defence And Space Unsponsored

EADSY

MRNA

STLA

VWAGY

Credit Suisse&#39;s $17B Of AT1 Debt Written Down To Zero, Richard Branson&#39;s Virgin Orbit Plans Insolvency, Court Freezes Volkswagen&#39;s Russian Assets: Today&#39;s Top Stories

Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine &#39;Just In Case&#39;

Movers

LGND

TVTX

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment

BLUE

QURE

FDA Approves UniQure&#39;s Hemgenix, First Hemophilia B Gene Therapy For Adults

Contracts

Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines

CSL Ltd

ALT5 Sigma Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTS#NASDAQ">ALTS</a>), a leading fintech innovator specializing in blockchain-powered technologies, is pleased to announce a partnership with Odoo, a globally recognized provider of fully integrated business applications. This collaboration will integrate ALT5 Pay into Odoo's suite of POS, eCommerce, and ERP systems, empowering Odoo's 13 million users across 170 countries with seamless cryptocurrency payment solutions.
Through this partnership, Odoo customers can easily integrate ALT5 Pay using simple API connections and widgets developed and supported by ALT5 Sigma. By leveraging the ALT5 Sigma platform, Odoo users will gain access to secure and innovative solutions for accepting a wide range of cryptocurrencies within their business applications. This initiative underscores Odoo's commitment to staying at the forefront of financial technology trends and expanding payment flexibility for its customers.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

ALTS

ALT5 Sigma Teams Up with Odoo to Bring Crypto Payments to Millions of Businesses

WIIM

Canadian National Railway shares are trading lower after Loop Capital downgraded the stock from Hold to Sell.

Cleveland-Cliffs Inc. (NYSE:<a href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) ("Cliffs") announced today that it intends to offer to sell, subject to market and other conditions, $750 million aggregate principal amount of Senior Guaranteed Notes due 2031 (the "Notes") in an offering that is exempt from the registration requirements of the Securities Act of 1933 (the "Securities Act"). The Notes will be guaranteed on a senior unsecured basis by Cliffs' material direct and indirect wholly-owned domestic subsidiaries, other than certain excluded subsidiaries.
Cliffs intends to use the net proceeds from the Notes for general corporate purposes, including the repayment of borrowings under its asset-based credit facility.

Offerings

Cleveland-Cliffs Plans $750M Bond Sale to Strengthen Finances

Canadian Pacific Kansas shares are trading lower after Loop Capital downgraded the stock from Buy to Hold.

Guidance Update
nCino also announced today that, while it has not completed closing the books on the fourth quarter and fiscal year 2025, it reaffirms the guidance provided on its third quarter fiscal year 2025 earnings call on December 4, 2024.

Guidance

NCNO

nCino Reiterated 2025 Outlook: Sees FY 2025 Non-GAAP OF $0.72-$0.73 Vs $0.68 Est.

Jefferies analyst Surinder Thind maintains Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) with a Buy and raises the price target from $34 to $42.

Jefferies Maintains Buy on Sprout Social, Raises Price Target to $42

Morgan Stanley analyst Robert Kad downgrades NextEra Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) from Overweight to Underweight and lowers the price target from $22 to $13.

Downgrades

Morgan Stanley Downgrades NextEra Energy Partners to Underweight, Lowers Price Target to $13

Macro Economic Events

Economics

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XPEV

Shares of US-listed Chinese stocks are trading lower following US tariffs on China.

CSC shares are trading lower after Loop Capital downgraded the stock from Buy to Hold and cut its price target from $40 to $34.

<a href="https://www.globenewswire.com/Tracker?data=rniWQ-sp1kdrIHh9ndw7fQ4cOpXqkxA0h6tCk6JheDeujFl7NN_THpE0ZDHHeLX2HtbrrVVMlc9t-p5YJw1RHt7vmXwSDgaa66vIjN9aEf4kVZy4Q2SG96Lru8Qy3tO7R9c5v9ZD6Kw-YDPQ06BnnqZRhHLcfd5fsSK9cQf3WMA=">nCino, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>), the leading provider of intelligent, best-in-class banking solutions, today announced the appointment of Sean Desmond as President and Chief Executive Officer and as a member of the company's Board of Directors, effective immediately. Desmond succeeds Pierre Naudé, who will continue to be actively involved in the Company as Executive Chairman of the Board to ensure a smooth transition.
"On behalf of the Board, we are pleased to have Sean lead nCino through its next phase of growth and innovation," said Pamela Kilday, the Company's Lead Independent Director. "After a thoughtful Board-led succession planning process and robust search that thoroughly assessed a large and diverse pool of external and internal candidates, we are confident Sean is the right leader to guide nCino forward. His extensive knowledge of all key facets of our business, paired with his experience scaling large, multi-national organizations, and forward-thinking approach to product innovation through data and AI, will help nCino capture new market opportunities and drive meaningful growth."
"It's a privilege to be the next President and CEO of nCino," said Sean Desmond. "nCino is an extraordinary company with best-in-class solutions, a culture of excellence, and a very happy and engaged customer base. This combination of attributes positions us for meaningful growth on a global scale. I'm incredibly honored to work with all the teams to deliver data-driven experiences through our intelligent platform that drive improved outcomes for our customers, and to provide long-term value for our investors."
Desmond added "My focus will be on mobilizing the company to meet the moment – which is to deliver the power of the only platform that stands on the foundation of the richest dataset in fintech, with embedded AI capabilities, to stay true to our mission of transforming financial services through innovation, reputation and speed."
"I am proud of what we have accomplished at nCino over the past 13 years, and it has been a privilege to guide that journey," said Pierre Naudé. "I've seen firsthand how Sean's leadership and experience has contributed to nCino's growth and success; he cares deeply about making customers successful and in the Company's ability to deliver market-leading innovation. Sean's vision for an AI and data-enabled platform with intelligence everywhere, along with his strong appreciation for customers, partners, and employees, sets a clear and exciting path as nCino continues to lead and evolve in a rapidly changing financial services industry. I am confident he is the right person to guide nCino forward, and I'm excited about this new era for the Company."
Desmond joined nCino in 2013 initially as Chief Customer Success Officer, ensuring the successful delivery and implementation of the nCino Platform to financial institutions around the world. His remit at the Company progressively expanded, and he most recently served as nCino's Chief Product Officer, overseeing the Product Development &amp; Engineering organization globally. In these roles, he managed approximately two-thirds of the company's employees.
Succeeding Desmond as Chief Product Officer is Chris Gufford, who has been the Executive Director and General Manager of nCino Commercial Banking since 2021.

Management

nCino Taps Sean Desmond as CEO Taking Over From Pierre Naudé Who Will Continue As Executive Chair

This agreement, reached by the companies, includes a drilling plan for 34 wells between April 2025 and June 2026, in addition to those being executed under the current development plan for the first months of 2025.
The agreement maintains the possibility of signing a new extension of the Development Plan in the future,&nbsp;subject to the macroeconomic environment, industry situation, and partners' interests.
Ecopetrol and Oxy will keep active an independent contract for the development of the Delaware sub-basin, will remain in force until 2027.

Ecopetrol And OXY Extend Permian Basin Development Plan; 34 New Wells Planned From April 2025 To June 2026

Jefferies analyst Surinder Thind maintains Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) with a Buy and raises the price target from $13 to $23.

SMWB

Jefferies Maintains Buy on Similarweb, Raises Price Target to $23

Morgan Stanley analyst Carlos De Alba downgrades United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) from Overweight to Equal-Weight and maintains the price target from $39 to $39.

Morgan Stanley Downgrades United States Steel to Equal-Weight, Maintains Price Target to $39

Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson &amp; Johnson company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an extension of marketing authorisation for a subcutaneous (SC) formulation of RYBREVANT&#xAE; (amivantamab) in combination with LAZCLUZE&#xAE;&nbsp;(lazertinib) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, and as a monotherapy for the treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after failure of platinum-based therapy.

Regulations

HALO

Johnson & Johnson's Janssen Wins Key EU Panel Support for New Lung Cancer Treatment

Jefferies analyst Brent Thill maintains SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) with a Buy and raises the price target from $17 to $21.

SEMR

Jefferies Maintains Buy on SEMrush Hldgs, Raises Price Target to $21

The adjusted operating margin guidance does not currently include any impact from the recently announced U.S. tariffs to be implemented on imports from Mexico, Canada and China.&nbsp;
The company is working to quantify the expected impact of these actions, as well as identify potential mitigation opportunities, and plans to provide an update on its fourth-quarter 2024 earnings conference call.

Baxter Remains Committed To Its Previously Announced 2025 Financial Objectives Of 4% - 5% Operational Sales Growth And ~16.5% Adjusted Operating Margin

ANAB

VNDA

Vanda Pharmaceuticals And Anaptys Announce Exclusive Global License Agreement For Imsidolimab; Anaptys To Receive $15M Upfront And 10% Royalty On Global Sales

Baxter Expects Results For Q4 And 2024 To Be Aligned With Continuing Operations Guidance Previously Provided In Q3 Earnings Announcement

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains First Hawaiian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHB#NASDAQ">FHB</a>) with a Market Perform and raises the price target from $28 to $31.

Keefe, Bruyette & Woods Maintains Market Perform on First Hawaiian, Raises Price Target to $31

Bowman Consulting Group Ltd. (the Company or Bowman) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWMN#NASDAQ">BWMN</a>), a national engineering services firm delivering infrastructure solutions and program management services to customers who own, develop and maintain the built environment, has been awarded a landmark two-year contract to provide high-resolution aerial orthoimagery for the State of Oklahoma ("State"). This initiative marks the first statewide leaf-off aerial mapping project undertaken in nearly 30 years and will deliver critical geospatial data for use by state agencies, municipalities and the public.
Bowman will utilize advanced high-altitude imaging capabilities, acquired in connection with the purchase of Surdex, to capture four-band, 6-inch resolution digital orthoimagery across approximately 70,000 square miles of Oklahoma during leaf-off seasons when tree cover is minimal. This coordinated timing, combined with real-time ground condition reports from local stakeholders, ensures clear visibility of critical features like creek beds, infrastructure and housing, enhancing the data's accuracy and versatility for various applications. The project will span the entire state, including a one-mile buffer beyond its borders, delivering comprehensive coverage to support both state-level operations and cross-boundary planning efforts.

BWMN

Bowman Consulting Wins Aerial Mapping Contract, First Statewide Project in Oklahoma in 30 Years

Press Releases

CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations

CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza

CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza

CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform

CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)

ONTF


Daniel GoldmanHouse (D-NY)	$50K - $100K	stock	Sale	Aug 13, 2023	Jul 10, 2023	House
Daniel GoldmanHouse (D-NY)	$15K - $50K	stock	Purchase	Mar 20, 2023	Feb 27, 2023	House

Government Trades

CSL Ltd

top performing CSLLY trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga